Home > Healthcare > Pharmaceuticals > Drug Delivery > Autoinjectors Market

Autoinjectors Market Analysis

  • Report ID: GMI5412
  • Published Date: Mar 2023
  • Report Format: PDF

Autoinjectors Market Analysis

Global Autoinjector Market Share By Type

To understand key trends  
Download Free Sample

The autoinjectors market is segmented by type into disposable and reusable. The disposable autoinjectors segment accounted for more than USD 37 billion in 2022. The segment's expansion can be attributed to rising chronic disease indications and improved technologically advanced autoinjector disease treatment efficacy. The category is anticipated to experience increasing demand due to patients' growing preference for autoinjectors for managing their own diseases. Moreover, disposable autoinjectors are made to allow patients to administer a precise dosage of medication. Also, an increase in the availability of products coupled with several other businesses working towards creating innovative technology will support the segment expansion.

Autoinjectors market is bifurcated based on the route of administration including subcutaneous and intramuscular. There has been a rising trend in patient preference towards self-administration of medication through autoinjectors in recent years. Autoinjectors provide patients with a more convenient way to self-administer their medication, which can be particularly beneficial for patients with chronic conditions that require frequent injections. Self-administration through autoinjectors gives patients more control over their treatment, allowing them to administer medication at a time and place that are most convenient to them. Such benefits offered by the autoinjectors will fuel the segment demand.

The autoinjectors market is segmented by route of administration into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, oncology, asthma, migraine, hormone therapy, and others. The rheumatoid arthritis segment held around 25% business share in the year 2022 and is projected to hold a moderate market size over the estimated timeline. Autoinjectors are devices that allow patients to self-administer medications with ease and accuracy. Rheumatoid arthritis (RA) affects approximately 1% of the global population, with women being more commonly affected than men. It is a chronic autoimmune disease that causes inflammation and pain in the joints. Autoinjectors can be used to administer disease-modifying antirheumatic drugs (DMARDs). Autoinjectors are beneficial for RA patients requiring frequent injections of their medication, as they provide a more convenient and efficient way to self-administer the medication.

Autoinjectors market by end-use is segmented into hospital & clinics, homecare settings and others. The homecare settings segment is estimated to proceed at an 13.4% CAGR during the projected timeframe. With the increasing demand for home-based healthcare services, the use of autoinjectors is expected to elevate. These devices can be used to administer a wide range of medications, including DMARDs, biologics, and vaccines. Thus, the expanding sophisticated healthcare infrastructure and accessibility will drive the demand for autoinjectors in homecare settings. This is because autoinjectors provide a more convenient and efficient way for patients to self-administer medications at home, which can reduce the burden on healthcare facilities and improve patient outcomes.

Global Autoinjector Market Size, By Region

To understand key market trends  
Download Free Sample

North America autoinjectors industry accounted for more than USD 25.5 billion in 2022 and will grow momentously during the analysis timeframe. The affordability of autoinjectors among the target population and ongoing technological developments in the field of managing chronic diseases are primarily responsible for the regional market forecasts. Also, the region's high healthcare spending on health care management and rising disposable income will propel the expansion of the North American market. Also, the substantial presence of well-established market participants and the favourable regulatory environment result in a number of product approvals and launches, particularly in the U.S. hence, propelling the regional industry landscape.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Global market share for autoinjectors was accounted at more than USD 55 billion in 2022 and is expected to record over 13% CAGR from 2023 to 2032.

Autoinjectors market share from the anaphylaxis therapy segment is forecasted to reach over USD 10 billion by end of 2032 owing to the rising prevalence and occurrence of anaphylaxis and food allergies.

Middle East & Africa autoinjectors industry is expected to reach over USD 12 billion by 2032 owing to the significant investments made in the development of new products by regional manufacturers.

AbbVie Inc., GlaxoSmithKline Plc., Mylan, Amgen, Becton, Ypsomed, Dickinson and Company, Eli Lilly and Company, Johnson & Johnson, and Antares Pharma, are some of the leading companies in the autoinjectors business.

Autoinjectors Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 230
  • Countries covered: 15
  • Pages: 175
 Download Free Sample